Pulmatrix Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Pulmatrix.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	23.9%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Aug 02

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

Jul 12

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Feb 22

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Oct 29

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Aug 16

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 14

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

May 27

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Feb 11

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pulmatrix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:PULM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	10	-10	-12	-11	N/A
6/30/2024	11	-11	-14	-13	N/A
3/31/2024	12	-9	-15	-14	N/A
12/31/2023	7	-14	-17	-16	N/A
9/30/2023	7	-16	-19	-19	N/A
6/30/2023	7	-18	-19	-18	N/A
3/31/2023	6	-18	-18	-18	N/A
12/31/2022	6	-19	-19	-19	N/A
9/30/2022	5	-22	-19	-19	N/A
6/30/2022	4	-25	-19	-18	N/A
3/31/2022	5	-24	-21	-20	N/A
12/31/2021	5	-23	-20	-20	N/A
9/30/2021	7	-19	-18	-18	N/A
6/30/2021	10	-21	-21	-20	N/A
3/31/2021	11	-19	-19	-19	N/A
12/31/2020	13	-19	-13	-12	N/A
9/30/2020	12	-20	-14	-14	N/A
6/30/2020	9	-13	-13	-13	N/A
3/31/2020	11	-20	7	7	N/A
12/31/2019	8	-21	3	3	N/A
9/30/2019	6	-21	3	3	N/A
6/30/2019	5	-22	3	3	N/A
3/31/2019	N/A	-20	-17	-17	N/A
12/31/2018	0	-21	-17	-17	N/A
9/30/2018	0	-21	-16	-16	N/A
6/30/2018	0	-20	N/A	-16	N/A
3/31/2018	0	-20	N/A	-15	N/A
12/31/2017	0	-18	N/A	-14	N/A
9/30/2017	0	-23	N/A	-14	N/A
6/30/2017	0	-22	N/A	-12	N/A
3/31/2017	0	-26	N/A	-12	N/A
12/31/2016	1	-28	N/A	-13	N/A
9/30/2016	1	-23	N/A	-14	N/A
6/30/2016	2	-24	N/A	-14	N/A
3/31/2016	1	-30	N/A	-14	N/A
12/31/2015	1	-26	N/A	-12	N/A
9/30/2015	1	-6	N/A	-11	N/A
6/30/2015	1	-13	N/A	-10	N/A
3/31/2015	0	-5	N/A	-9	N/A
12/31/2014	0	-6	N/A	-9	N/A
12/31/2013	1	-13	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PULM's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if PULM's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if PULM's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PULM's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PULM's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PULM's Return on Equity is forecast to be high in 3 years time

Pulmatrix Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 16%

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

Price target decreased to US$10.00

No longer forecast to breakeven

Price target increased to US$200

No longer forecast to breakeven

Recent updates

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

New major risk - Share price stability

Cullgen Inc. entered into an Agreement to acquire Pulmatrix, Inc. (NasdaqCM:PULM) in a reverse merger transaction

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$1.03 loss in 3Q 2023)

Pulmatrix, Inc., Annual General Meeting, Dec 18, 2024

Second quarter 2024 earnings released: US$1.59 loss per share (vs US$1.05 loss in 2Q 2023)

There Is A Reason Pulmatrix, Inc.'s (NASDAQ:PULM) Price Is Undemanding

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine (PUR3100)

First quarter 2024 earnings released: EPS: US$0.23 (vs US$1.22 loss in 1Q 2023)

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies